• Patient aged ≥ 18 years at inclusion,

• Patient with Ph+ CML-CP previously treated with two or more TKIs,

• Patient for whom a decision has been taken by the treating physician (investigator) to initiate treatment with asciminib according to his own practice, the drug label / Summary of Product Characteristics (SmPC), and regardless of study participation,

• Patient having given their non objection to participate to the study